CINECA IRIS Institutional Research Information System

BONORA, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.121
EU - Europa 13.365
AS - Asia 10.736
SA - Sud America 1.722
AF - Africa 386
OC - Oceania 93
Continente sconosciuto - Info sul continente non disponibili 26
Totale 48.449
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.650
SG - Singapore 4.071
CN - Cina 3.866
IT - Italia 2.393
DK - Danimarca 1.830
DE - Germania 1.520
IE - Irlanda 1.321
BR - Brasile 1.306
FR - Francia 1.124
SE - Svezia 1.080
FI - Finlandia 810
UA - Ucraina 736
GB - Regno Unito 680
KR - Corea 674
VN - Vietnam 599
AT - Austria 446
IN - India 374
PL - Polonia 348
CA - Canada 261
NL - Olanda 233
ID - Indonesia 232
ES - Italia 226
HK - Hong Kong 169
JP - Giappone 159
ZA - Sudafrica 154
MX - Messico 152
RU - Federazione Russa 128
AR - Argentina 126
RO - Romania 88
BE - Belgio 85
AU - Australia 83
TW - Taiwan 83
TH - Thailandia 75
TR - Turchia 73
CH - Svizzera 69
CO - Colombia 64
CL - Cile 61
PE - Perù 56
BD - Bangladesh 55
PK - Pakistan 55
EC - Ecuador 47
CZ - Repubblica Ceca 46
GR - Grecia 36
IR - Iran 34
PT - Portogallo 32
IQ - Iraq 30
UZ - Uzbekistan 29
KE - Kenya 25
IL - Israele 24
EU - Europa 22
EG - Egitto 21
NG - Nigeria 21
PH - Filippine 20
UG - Uganda 20
SN - Senegal 19
PY - Paraguay 18
SA - Arabia Saudita 18
VE - Venezuela 18
ET - Etiopia 17
HR - Croazia 17
MA - Marocco 17
BG - Bulgaria 15
HU - Ungheria 15
AE - Emirati Arabi Uniti 14
BO - Bolivia 12
LT - Lituania 12
NO - Norvegia 12
SK - Slovacchia (Repubblica Slovacca) 12
UY - Uruguay 12
DO - Repubblica Dominicana 11
JO - Giordania 11
NP - Nepal 11
TN - Tunisia 11
NZ - Nuova Zelanda 10
RS - Serbia 9
LV - Lettonia 8
MY - Malesia 8
PA - Panama 8
TZ - Tanzania 8
BY - Bielorussia 7
CR - Costa Rica 7
DZ - Algeria 7
GT - Guatemala 7
KZ - Kazakistan 7
MU - Mauritius 7
MW - Malawi 7
NA - Namibia 6
SD - Sudan 6
AZ - Azerbaigian 5
CU - Cuba 5
MZ - Mozambico 5
TT - Trinidad e Tobago 5
ZW - Zimbabwe 5
AL - Albania 4
CD - Congo 4
EE - Estonia 4
GH - Ghana 4
LA - Repubblica Popolare Democratica del Laos 4
LU - Lussemburgo 4
MD - Moldavia 4
Totale 48.359
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.773
Beijing 2.542
Singapore 2.019
Chandler 1.953
Dublin 1.314
Houston 1.189
Ashburn 1.158
Santa Clara 908
Fairfield 881
Villeurbanne 622
Wilmington 601
Torino 554
Jacksonville 530
Dearborn 479
Medford 469
Princeton 441
Woodbridge 432
Redwood City 384
Columbus 367
Seattle 367
Vienna 339
Nyköping 314
Warsaw 309
Cambridge 271
Los Angeles 243
Buffalo 229
Turin 224
Milan 221
Hefei 191
Dallas 189
Pisa 185
Munich 178
Seoul 173
New York 172
Boston 155
Jakarta 142
Ho Chi Minh City 136
Boardman 132
Fremont 130
São Paulo 129
Hong Kong 128
Dong Ket 116
Guangzhou 109
Bengaluru 106
Nuremberg 105
Toronto 94
Shanghai 89
Hanoi 84
Helsinki 83
Verona 75
Paris 71
San Diego 68
Nanjing 66
Hangzhou 63
Chicago 62
Rome 60
Brussels 59
Rio de Janeiro 58
Frankfurt am Main 57
Cape Town 54
Redondo Beach 53
London 52
Norwalk 52
Taipei 52
Turku 52
Kunming 49
Washington 45
Lima 43
Santiago 40
Tokyo 39
Nürnberg 38
Silver Spring 38
Phoenix 37
Amsterdam 36
Ottawa 36
Falls Church 35
San Francisco 35
Pune 34
Buenos Aires 33
Chengdu 33
Omaha 32
Jinan 31
Belo Horizonte 30
Mexico City 30
The Dalles 30
Montreal 29
Brooklyn 28
Madrid 28
Atlanta 27
Mountain View 27
Changsha 26
Zhengzhou 26
Brasília 24
Mumbai 24
Arlington 23
Brno 23
Lachine 23
Barcelona 21
Hebei 21
Minneapolis 21
Totale 28.008
Salva come PNG Salva come JPEG
Nome #
Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? 860
Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system. 794
Cytomegalovirus central nervous system compartmentalization in a patient presenting with AIDS 659
Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era 554
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 512
The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment 471
Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. 457
High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis 432
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients 395
A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs 365
Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study 364
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. 354
HIV-1 Very Low Level Viremia is Associated with Virological Failure in HAART-treated Patients 344
Heart failure in patients with human immunodeficiency virus: a review of the literature. 342
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. 340
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 321
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment 315
Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting 312
CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose 310
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 292
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study) 278
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. 274
Raltegravir penetration in seminal plasma of healthy volunteers. 273
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid 273
Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination 271
A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease 265
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 261
Presence of EBV DNA in Cerebrospinal Fluid is Associated with Greater HIV RNA and Inflammation 259
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis 258
Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients 255
Acute HIV infection: Improved algorithms for HIV testing. 248
Prevalence and predictors of blood-brain barrier damage in the HAART era. 246
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV). 246
Extra Corporeal Membrane Oxygenation (ECMO) in three HIV-positive patients with acute respiratory distress syndrome 231
Pharmacogenetics of Antiretrovirals' Penetrations into Cerebrospinal Fluid 231
Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia 222
Descrittiva della farmacocinetica (PK) e della farmacogenetica (PG) dell'Efavirenz in una coorte di popolazione italiana 221
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 216
In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis 215
Cardiovascular disease in HIV patients: from bench to bedside and backwards 208
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 207
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 206
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 204
An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients 202
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting 201
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks 200
Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines 199
West African Immigrants and New Patterns of Malaria Imported to North Eastern Italy. 197
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. 197
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. 197
Etravirine Plasma Exposure is Associated with Virological Efficacy in Treatment-experienced HIV-positive Patients. 196
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens 195
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014 195
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients. 195
Failure of prophylaxis against PCP in patients with HIV infection. 194
TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE 193
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 191
Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting 191
A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. 191
Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV 187
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. 184
Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting 181
INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS 180
Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy? 179
Role of therapeutic drug monitoring in a patient with human immunodeficiency virus infection and end-stage liver disease undergoing orthotopic liver transplantation 179
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. 178
Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. 178
High incidence of infections in HIV-positive patients treated for lymphoproliferative disorders 178
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. 178
Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients 177
An improved HPLC fluorimetric method for the determination of enfuvirtide plasma levels in HIV-infected patients 175
Pharmacokinetic Determinants of Immunovirological Response in HIV Very Late Presenters 175
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 174
Undetectable Ritonavir Plasma Concentrations in Different Boosted PI-based Regimens as a Marker of Non-Adherence: analysis of a large TDM Registry 173
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 173
GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY 173
Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. 172
Pharmacokinetics (PK) of the co-administration of raltegravir (RAL) and amlodipine (AML) to male and female healthy volunteers 171
Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting 171
Efficacy, Safety and Pharmacokinetics of Atazanavir (200 mg twice-daily) plus Raltegravir (400 mg twice-daily) Dual Regimen in the Clinical Setting 169
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. 169
Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics 169
Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject 168
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 168
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. 167
Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring 167
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients 166
What do we know about tailoring treatment with tenofovir? 166
Clinical pharmacology of complex regiment of antiretroviral therapy including Etravirine, Maraviroc and Raltégravir. 166
Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study. 165
HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients 165
MONITORING OF VIROLOGICAL AND PHARMACOLOGICAL CEREBROSPINAL FLUID PARAMETERS IN HAART-TREATED HIV-POSITIVE PATIENTS IN THE CLINICAL SETTING 164
AISF position paper on HCV in immunocompromised patients 164
Pharmacokinetics of the Dual NRTI- and Protease Inhibitor-sparing Regimen Raltegravir plus Nevirapine in HIV-1+ Patients 162
High Interpatient Variability of Raltegravir Cerebrospinal Fluid Concentrations in HIV-positive Patients: a Pharmacogenetic Analysis 162
Intracellular accumulation of the new integrase inhibitors elvitegravir and dolutegravir in HIV patients 162
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers 159
Viral rebound after switch to Maraviroc-Raltegravir dual therapy 159
Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. 159
Continuous intravenous infusion of enfuvirtide in an out-clinic patient with a multi resistent HIV strain and severe injection-site reactions 159
Totale 24.486
Salva come PNG Salva come JPEG
Categoria #
all - tutte 147.055
article - articoli 0
book - libri 0
conference - conferenze 27.989
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 175.044
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.159 0 0 0 0 404 359 323 159 447 371 316 780
2021/20226.295 540 453 545 604 429 439 562 512 352 256 714 889
2022/20236.212 631 368 123 579 651 1.584 462 455 676 122 330 231
2023/20242.828 355 457 158 159 240 402 78 180 55 119 233 392
2024/20257.211 117 318 306 648 1.621 458 220 467 816 467 589 1.184
2025/20265.359 1.327 725 900 1.737 670 0 0 0 0 0 0 0
Totale 50.130